Clinician-Input Study (CIS-PD): how the Fox Wearable Companion Application can influence treatment and care in Parkinson’s disease (P3.048)

Objective: To assess the utility of mobile and wearable device data from Parkinson’s disease (PD) patients in clinical practice and to develop a data display dashboard format that is informative for patient care management. Background: Data captured by mobile and wearable devices have the potential to inform clinical care of PD. The Michael J. Fox Foundation partnered with Intel Corporation to develop the Fox Wearable Companion app , a mobile and wearable application for PD patients. The application is part of Intel® Pharma Analytics Platform, an edge to cloud platform that collects 24×7 sensory data and remote electronic patient reported outcomes (ePROs). Design/Methods: The study is being conducted at 4 US sites. Participating clinicians (N=13) enroll 2–4 patients. Patients install the app on their own smartphone to record all medication intake and symptom severity 3 times/day, and are provided an Apple watch to wear 12 hours/day and 25 days/month minimum. In-clinic visits occur at baseline, 2 weeks, 1, 3, and 6 months. During visits, clinicians perform assessments and review a dashboard that dynamically displays the data. Clinicians provide feedback on data visualization and utility within the dashboard. Clinicians participate in monthly focus groups to suggest iterative changes to the dashboard. Results: The study launched in June 2017 and completed enrollment (N=51) in August 2017. Follow-up visits will conclude by February 2018. Four clinician focus groups have occurred to-date. As of October 1, patient compliance for streaming data from the wearable device is 67%, with over 40,000 hours of data streamed in total. A more complete picture of compliance and study methodology will be available by the meeting. Conclusions: Data from mobile/wearable technologies have the potential to aid clinician understanding of patients’ experiences outside the clinic and inform clinical care. This novel approach to data collection and tool development has the potential to meaningfully impact PD care. Study Supported by: The Michael J. Fox Foundation for Parkinson’s Research Disclosure: Dr. Daeschler has nothing to disclose. Dr. Elm has nothing to disclose. Dr. Klintworth has nothing to disclose. Dr. Afek has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Intel Corporation. Dr. Afek has received compensation for serving on the Board of Directors of Intel Corporation. Dr. Lazar has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Intel Corporation. Dr. Lazar has received compensation for serving on the Board of Directors of Intel Corporation. Dr. Simuni has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acadia Abbvie Anavex Allergan Avid Civitas Accorda GE Medical Eli Lilly Cynapsus Ibsen IMPAX Merz Inc National Parkinson Foundation Navidea Sanofi Pfizer Sunovion TEVA UCB Pharma Voyager US World Meds. Dr. Simuni has received research support from Civitas, Acorda, Biogen, Roche Neuroderm.